Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Maple Syrup Urine Disease Type II

Metabolic & Lysosomal

Maple Syrup Urine Disease Type II Clinical Trials

Also called MSUD Type II, branched-chain ketoaciduria, intermediate-form MSUD

Maple syrup urine disease (MSUD) is an autosomal recessive disorder of branched-chain amino acid breakdown. Strictly, type II refers to MSUD caused by variants in the DBT gene, which encodes the E2 subunit; DBT variants have been reported in the thiamine-responsive form, though classic disease can also occur.

In plain words, maple syrup urine disease type II is a rare condition where the body only partly breaks down certain protein building blocks. These build up in the blood, especially during illness or fasting, and can harm the brain and development.

Get an email when new Maple Syrup Urine Disease Type II trials open or the FDA decides. Get alerts

Maple Syrup Urine Disease Type II

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 1 study with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines0

No medicine's current FDA label names Maple Syrup Urine Disease Type II yet.

Maple Syrup Urine Disease Type II has no FDA-approved medicines, 1 open or active clinical trial (1 recruiting), and no pending FDA decision.

Labels checked October 21, 2026.Download the data

Latest for Maple Syrup Urine Disease Type II

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Maple Syrup Urine Disease Type II

This page covers the intermediate and intermittent forms, which result from partial deficiency of the branched-chain alpha-ketoacid dehydrogenase (BCKDC) complex, a mitochondrial enzyme complex composed of four subunits required for degradation of leucine, isoleucine, and valine. Intermediate MSUD has residual enzyme activity of approximately 3-30% of normal, allowing some branched-chain amino acid (BCAA) metabolism but with progressive accumulation of toxic metabolites during catabolic stress (illness, infection, fasting).

Keep reading about Maple Syrup Urine Disease Type II

Unlike the neonatal presentation of classic MSUD, intermediate MSUD typically presents from months to years of age with progressive symptoms. Clinical features include developmental delay and progressive neurologic deterioration, muscle tone abnormalities (hypotonia alternating with hypertonia and spasticity), seizures, lethargy, behavioral changes, and metabolic acidosis during decompensation.

The characteristic maple-scented urine odor occurs during acute metabolic decompensation. Accumulation of branched-chain amino acids and their metabolites (particularly leucine metabolites) causes neurologic injury through multiple mechanisms including mitochondrial dysfunction and excitotoxicity. Without treatment, progressive neurodegeneration leads to severe disability.

What are the symptoms of Maple Syrup Urine Disease Type II?

These are common symptoms of Maple Syrup Urine Disease Type II, and how strong they are varies from person to person.

  • Progressive developmental delay and neurologic deterioration
  • Hypotonia and hypertonia
  • Seizures and lethargy
  • Metabolic acidosis during decompensation
  • Elevated branched-chain amino acids in blood and urine
  • Maple-scented urine

Who gets Maple Syrup Urine Disease Type II?

MSUD Type II shows autosomal recessive inheritance, affecting males and females equally across all ethnic groups. Presentation typically occurs from approximately 6 months to 3-4 years of age, though cases with delayed presentation into later childhood have been reported.

The age of presentation depends on the residual enzyme activity level and the specific genetic mutations; patients with slightly higher residual activity present later. Type II is rare, with significantly lower prevalence than classic (Type I) MSUD.

MSUD is far more common in some communities with founder variants, such as the Old Order Mennonite population, where it affects about 1 in 380 newborns, according to MedlinePlus. Prognosis with treatment is variable; early diagnosis and strict dietary management can slow progression and optimize developmental outcomes. Recurrence risk for siblings of affected individuals is 25% per pregnancy (assuming both parents are carriers). Prenatal diagnosis is possible through genetic testing or enzyme activity measurement in amniotic fluid.

Next steps: find trials you might fitsee what is being testedget help payingget alerts

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Maple Syrup Urine Disease Type II

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Maple Syrup Urine Disease Type II resources

Reputable organizations and medical references for learning more about Maple Syrup Urine Disease Type II, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Maple Syrup Urine Disease Type II

Use this Maple Syrup Urine Disease Type II clinical trial finder to see the 1 study recruiting patients in the United States and worldwide, with eligibility criteria in plain English. It does not test a treatment; it follows patients over time. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

1 active trial worldwide
Filter:
Sort:
RecruitingObservational study, no treatment givenHasn't posted an update in over a yearNCT04602325

Systemic Biomarkers of Brain Injury From Hyperammonemia

Sponsor: Children's National Research Institute

Ammonia is a waste product of protein and amino acid catabolism and is also a potent neurotoxin. High blood ammonia levels on the brain can manifest as cytotoxic brain edema and vascular compromise leading to intellectual and developmental disabilities. The following aims are proposed:

Ages 7 Years to 18 Years1 location
Started Jul 2020Updated 2 years agoEst. Jul 2026
Find Maple Syrup Urine Disease Type II trials near you, ranked by distance →
Active trial locations1 city in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.

Trial Pipeline

Jan 2021 to May 2027
2021
2023
2025
2027
now
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Maple Syrup Urine Disease Type II trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Maple Syrup Urine Disease Type II foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Maple Syrup Urine Disease Type II patient communities

Facebook groups, Reddit communities and YouTube channels where Maple Syrup Urine Disease Type II patients, caregivers and advocacy groups talk.

Questions people ask about Maple Syrup Urine Disease Type II